Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications

Area of Science:

• Pharmacology
• Drug Metabolism
• Infectious Diseases

Background:

• Lopinavir-ritonavir is utilized for SARS-CoV-2 treatment.
• Ritonavir potently inhibits CYP P450 3A4, increasing lopinavir plasma concentrations.
• Ritonavir also affects other CYP enzymes, leading to drug interactions.

Purpose of the Study:

• To identify and enumerate drug-drug interactions between lopinavir-ritonavir and cardiac medications.
• To highlight potential risks in patients with co-occurring SARS-CoV-2 and cardiovascular conditions.
• To guide clinicians in managing polypharmacy involving antiviral and cardiac therapies.

Main Methods:

• Review of known pharmacokinetic properties of lopinavir-ritonavir.
• Analysis of drug-drug interaction profiles of ritonavir with common cardiac drugs.
• Clinical scenario evaluation for co-prescription challenges.

Main Results:

• Ritonavir's inhibition of CYP2D6 and induction of other CYP enzymes can alter cardiac drug metabolism.
• Co-administration of lopinavir-ritonavir with cardiac medications may lead to significant drug toxicity.
• Potential for serious adverse events in patients with acute coronary syndrome or heart failure.

Conclusions:

• Clinicians must be aware of ritonavir-mediated drug-drug interactions.
• Alternative antiviral or cardiac therapies should be considered to ensure patient safety.
• Careful management is crucial to avoid toxicity and improve patient outcomes.